건강보험 청구자료를 이용한 궤양성 대장염 치료제의 처방 양상과 전신 스테로이드 처방에 미치는 영향요인
Patterns of Ulcerative Colitis Treatments and Factors Affecting the Prescribing of Systemic Corticosteroid using Health Insurance Claims Database
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objective: To analyze the prescription patterns for the treatment of ulcerative colitis (UC) and to investigate factors co-occurring with systemic corticosteroid use. Methods: We used patient-level data from Korean National Health Insurance claims database to identify patients diagnosed with UC (ICD-10 code : K51) and their medications prescribed for UC between January 1 and Decemeber 31, 2017. We found that medications for UC treatment were 5-aminosalicylic acid (5-ASA), immunomodulators, biologics, and corticosteroids. We presented the prescription pattern according to the sex, age group, type of health insurance, site of UC, type of medical institution, and concomitant medication. To evaluate factors associated with prescription of systemic corticosteroids for UC, we used a multivariate logistic regression model to estimate adjusted odds ratios (aORs) and their 95% confidence intervals (CIs). Results: Of 1,469 UC patients, 74.5% used 5-ASA and 15.2% used systemic corticosteroids. 5-ASA constituted 77.5% of all prescriptions and systemic corticosteroids accounted for 13.1%. The most widely used therapy was 5-ASA monotherapy (54.8%), followed by a double therapy with 5-ASA and immunomodulators (8.2%) or 5-ASA and systemic corticosteroids (7.2%). Systemic corticosteroids were more likely to be prescribed with immunomodulators (aOR=1.88, 95% CI=1.54- 2.28) and biologics (aOR=2.82, 95% CI=2.28-3.50) than without them. Conclusions: We found that 15.2% of UC patients were prescribed with a systemic corticosteroid, which is less than reported previously. Systemic corticosteroids were more likely to be prescribed with immunomodulators and biologics.
Abstract
Objective: To analyze the prescription patterns for the treatment of ulcerative colitis (UC) and to investigate factors co-occurring with systemic corticosteroid use. Methods: We used patient-level data from Korean National Health Insurance claims database to identify patients diagnosed with UC (ICD-10 code : K51) and their medications prescribed for UC between January 1 and Decemeber 31, 2017. We found that medications for UC treatment were 5-aminosalicylic acid (5-ASA), immunomodulators, biologics, and corticosteroids. We presented the prescription pattern according to the sex, age group, type of health insurance, site of UC, type of medical institution, and concomitant medication. To evaluate factors associated with prescription of systemic corticosteroids for UC, we used a multivariate logistic regression model to estimate adjusted odds ratios (aORs) and their 95% confidence intervals (CIs). Results: Of 1,469 UC patients, 74.5% used 5-ASA and 15.2% used systemic corticosteroids. 5-ASA constituted 77.5% of all prescriptions and systemic corticosteroids accounted for 13.1%. The most widely used therapy was 5-ASA monotherapy (54.8%), followed by a double therapy with 5-ASA and immunomodulators (8.2%) or 5-ASA and systemic corticosteroids (7.2%). Systemic corticosteroids were more likely to be prescribed with immunomodulators (aOR=1.88, 95% CI=1.54- 2.28) and biologics (aOR=2.82, 95% CI=2.28-3.50) than without them. Conclusions: We found that 15.2% of UC patients were prescribed with a systemic corticosteroid, which is less than reported previously. Systemic corticosteroids were more likely to be prescribed with immunomodulators and biologics.
참고문헌 (27)
- 양동훈, "한국인에서 궤양성 대장염은 증가하는가?", 대한내과학회지, 76(6), pp.637~642 (2009), 대한내과학회
- Greenberg GR, "Oral budesonide for active Crohn’s disease", New Engl J Med, 331(13), pp.836~841 (1994)
- Mantzaris GJ, "Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid-dependent Crohn’s disease", Inflamm Bowel Dis, 15(3), pp.375~382 (2008)
- Reinisch W, "Response and remission are associated with improved quality of life, employment and disability status, hours worked, and productivity of patients with ulcerative colitis", Inflamm Bowel Dis, 13(9), pp.1135~1140 (2007)
- Bernklev T, "Course of disease, drug treatment and health-related quality of life in patients with inflammatory bowel disease 5 years after initial diagnosis", Eur J Gastroenterol Hepatol, 17(10), pp.1037~1045 (2005)
- 나수영, "염증성 장질환에서 치료 전략의 진화", 대한소화기학회지, 71(2), pp.61~68 (2018), 대한소화기학회[DOI]
- 장병익, "염증성장질환 치료 패러다임의 변화", 대한소화기학회지, 65(5), pp.268~272 (2015), 대한소화기학회
- Kim YM, "Clinical characteristics and longterm course of ulcerative colitis in Korea", Intest Res, 4(1), pp.12~21 (2006)
- 하정은, "국내 염증성장질환의 약물치료 및 약제비 현황: 2010-2014 국민건강보험자료 활용 연구", 한국임상약학회지, 29(2), pp.79~88 (2019), 한국임상약학회[DOI]
- 김동숙, "건강보험 자료를 이용한 만성신부전 환자의 신독성 약물사용 현황", 약 학 회 지, 53(3), pp.138~144 (2009), 대한약학회
- 최창환, "궤양성 대장염 치료 가이드라인 개정판", 대한소화기학회지, 69(1), pp.1~28 (2017), 대한소화기학회[DOI]
- 진윤태, "궤양성 대장염의 최신치료", 대한내과학회지, 76(6), pp.654~660 (2009), 대한내과학회
- Kim HJ, "Incidence and natural course of inflammatory bowel disease in Korea, 2006-2012: a nationwide population-based study", Inflamm Bowel Dis, 21(3), pp.623~630 (2015)
- Wee Khoon Ng, "Changing epidemiological trends of inflammatory bowel disease in Asia", Intestinal research, 14(2), pp.111~119 (2016), 대한장연구학회
- Chang D, "Follow-up of ulcerative colitis : Shortterm outcome to medical treatment and relapse rates", Korean J Gastroenterol, 26, pp.907~918 (1994)
- Jung Won Lee, "Inflammatory Bowel Disease Cohort Studies in Korea: Present and Future", Intestinal research, 13(3), pp.213~218 (2015), 대한장연구학회
- 채현범, "궤양성 대장염에서 진단시기별 예후의 차이", 대한소화기학회지, 64(2), pp.93~97 (2014), 대한소화기학회
- Kim CG, "Clinical features of Crohn's disease in Korea", Korean J Gastroenterol, 40(3), pp.173~180 (2002)
- 예병덕, "크론병 진단 가이드라인", 대한소화기학회지, 53(3), pp.161~176 (2009), 대한소화기학회
- Ho GT, "The efficacy of corticosteroid therapy in inflammatory bowel disease : analysis of a 5-year UK inception cohort", Aliment Pharmacol Ther, 24(2), pp.319~330 (2006)
- Truelove SC, "Cortisone in ulcerative colitis", BMJ, 2, pp.1041~1048 (1955)
- Sandborn WJ, "Once-daily budesonide MMX® extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study", Gastroenterology, 143(5), pp.1218~1226. e2 (2012)
- Travis SP, "Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study", Gut, 63(3), pp.433~441 (2014)
- Campieri M, "Oral beclometasone dipropionate in the treatment of extensive and left?sided active ulcerative colitis : a multicentre randomised study", Aliment Pharmacol Ther, 17(12), pp.1471~1480 (2003)
- Mowat C, "Guidelines for the management of inflammatory bowel disease in adults", Gut, 60(5), pp.571~607 (2011)